INFANT BACTERIAL THERAPEUTICS AB The report is available on IBT´s website, https://ibtherapeutics.com under the section Ïnvestors & Media – Financial Reports”.
Contacts
Staffan Strömberg, CEO
info@ibtherapeutics.com
+46 76 219 37 38
About Us
IBT is a pharmaceutical company whose purpose is to develop and commercialize drugs for diseases affecting premature babies or where IBT's unique expertise in the field of drugs with live bacteria as active substances can be a key competitive factor.
IBT's main focus is the drug candidate IBP-9414, whose development program is designed to show a reduced incidence of necrotizing enterocolitis ("NEC") and improved gastrointestinal function ("SFT") when treated with IBP-9414's active substance Lactobacillus reuteri;a bacterial strain naturally found in human breast milk. IBP-9414, is expected to be the first product in the new class of biologics called "Live Biotherapeutic Products" for premature infants. Upon approval, it would be the first product to prevent NEC and improve Sustained Feeding Tolerance (SFT) in newborns.
The drug development of IBP-9414 is currently in its final stages and IBT expects to receive regulatory approval in 2025 for this important product for premature babies.
The portfolio also includes additional drug candidates, IBP-1016, IBP-1118 and IBP-1122. IBP-1016, for the treatment of gastroschisis, a life-threatening and rare disorder in which children are born with externalized gastrointestinal organs. IBP-1118 to prevent retinopathy of prematurity (ROP), one of the leading causes of blindness in premature babies, and IBP-1122 to eliminate vancomycin-resistant enterococci (VRE), which cause antibiotic-resistant hospital infections.
Through the development of these drugs, IBT can address medical needs where no treatments are currently available.
This information is information that
Attachments
IBT Annual Report 2023
IBT Annual report 2023
© Modular Finance, source
